Fierce Pharma

Verastem launches ‘Reimagine’ campaign to move ovarian cancer drugs into earlier lines

May 1, 2026 4:13am

Verastem Oncology has launched a marketing campaign for its co-packaged cancer drugs to drive use of the treatment in earlier lines of therapy.

BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio

Apr 30, 2026 11:23am

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition.

Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's

Apr 30, 2026 11:25am

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at least one set of analysts—isn’t sweating what appears to be a slower-than-expected liftoff compared with Novo Nordisk’s rival Wegovy pill.

Merck's growth products Winrevair, Ohtuvayre trending in opposite directions

Apr 30, 2026 11:15am

While Merck's PAH treatment Winrevair continued its upward trajectory, another of its growth products, COPD medicine Ohtuvayre, took a step back in the first quarter.

Merck bats for heart disease awareness with new baseball-inspired campaign

Apr 30, 2026 4:29am

Merck is making its pitch that high levels of so-called “bad cholesterol” can increase the risk of heart attack or stroke with its new “Playing with Heart” project.

Europe’s drug regulator sets up new group to counter vaccine hesitancy

Apr 30, 2026 2:23am

The European Medicines Agency (EMA) has launched an advisory group designed to help boost “vaccine confidence” amid growing hesitancy in the region.

Amarox recalls batch of antidepressants in UK over packaging mix-up

Apr 30, 2026 7:29am

Amarox, the U.K. unit of India’s Hetero Group, issued a voluntary recall of one batch of sertraline tablets in Britain after a patient found two different antidepressants packaged together.

Novartis rounds out $23B US investment push with plans for North Carolina API plant

Apr 29, 2026 4:26pm

Novartis will construct an active pharmaceutical ingredient (API) facility in Morrisville, North Carolina, the company said Thursday. The 56,200 square-foot plant will manufacture compounds for solid-dose tablets, capsules and RNA therapeutics.

Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals'

Apr 30, 2026 5:26am

The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s prostate cancer drug Nubeqa.

Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs

Apr 30, 2026 3:21am

Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its inhaled versions of approved respiratory drugs.

US drugmaker’s reputations shift quickly amid political pressures, job cuts: survey

Apr 29, 2026 9:07am

Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in the past year as the businesses have contended with political pressures, PatientView said.

AstraZeneca CEO's conservative MFN model excludes reference markets from forecast

Apr 29, 2026 2:40pm

As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a “very conservative” way to model the fallout would be removing the eight reference markets from future product forecasts.

AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde

Apr 29, 2026 11:21am

Immunology med Skyrizi charted sales growth of 30.9% over 2026's first quarter, bringing in $4.48 billion as AbbVie's top earner.

With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorphosis

Apr 29, 2026 2:31pm

While Teva Pharmaceutical’s multiyear growth streak under CEO Richard Francis showed signs of leveling off, the company still topped Wall Street estimates in 2026’s first quarter, buoyed by the impressive performance of branded drugs like Austedo, Uzedy and Ajovy.

Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years

Apr 29, 2026 10:49am

As regulatory delays continue to plague Regeneron's Eylea franchise, quarterly sales for the eye disease medicine have dropped below $1 billion for the first time since the second quarter of 2018.

New GSK CEO’s first quarter boosted by Shingrix surge as Exdensur stumbles in switch trial

Apr 29, 2026 9:48am

In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales record while its closely watched asthma launch Exdensur showed “early signals” of commercial progress despite a recent trial flop.

Pfizer looks to jump start Elrexfio with topline win in second-line myeloma

Apr 29, 2026 8:42am

With a new positive trial readout, the company is aiming to reach a broader set of patients with its multiple myeloma bispecific Elrexfio.

Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout

Apr 29, 2026 9:28am

As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med and its developer KalVista.

AstraZeneca restarts £300M investment in UK, but Merck not budging

Apr 29, 2026 9:34am

AstraZeneca has announced it will resume a £300 million investment program in the U.K., seven months after freezing the plans in frustration at national government drug pricing negotiations.

Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies

Apr 28, 2026 4:25pm

Novartis CEO Vas Narasimhan says that Europe needs a “complete rethink” on how it prices its drugs, warning that the entrance of new pharmaceuticals into its markets could be delayed.

Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts

Apr 28, 2026 2:55pm

Pfizer now anticipates its Vyndamax sales to remain “relatively stable” from 2028 through mid-2031, it said.

FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting

Apr 28, 2026 2:22pm

The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead of an upcoming advisory committee meeting, the first such gathering in about nine months.

FDA turns up heat on Amgen, proposing to rescind approval of Tavneos

Apr 28, 2026 11:02am

The FDA has told Amgen that it is proposing to withdraw the approval of the rare disease drug Tavneos. The FDA cited new information that indicates that data was "manipulated" to facilitate the approval of Tavneos. In addition, the FDA is “increasingly concerned about the safety of Tavneos,” pointing to cases of serious drug-induced liver injury.

With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms

Apr 24, 2026 2:27pm

After recalibrating its production strategy in the late 2010s to help meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential approval of a next-generation multiple myeloma cell therapy later this year.

Rocket sells priority review voucher for $180M after Kresladi gene therapy approval

Apr 28, 2026 10:50am

Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher, striking a $180 million sale that reflects the high market demand for a speedy FDA review.